|
| Compound | Inflammasome target | Disease/animal model | Reference |
|
| BAY 11-7082 (NF-κB inhibitor) | NLRP3 | Paraquat-induced acute kidney injury model (rat) | [147] |
| Allopurinol (oxidase inhibitor) | Need to be specified | Glycerol-induced acute kidney injury model (rat) | [148] |
| 4-Hydroxycinnamaldehyde-galactosamine | NLRP3 | LPS-induced renal inflammation (mice) | [149] |
| Harmine | NLRP3 | LPS-induced renal inflammation model (mice) | [150] |
| Artemisinin | NLRP3 | 5/6 nephrectomy (rat) | [151] |
| Rotenone (inhibitor of mitochondrial complex I) | NLRP3 | Aldosterone-infused renal nephropathy model (rat) | [152] |
| Hydroxychloroquine | NLRP3 | Ischemia-reperfusion model (mice) | [73] |
| 1,3-Butanediol (inhibitor of the NLRP3) | NLRP3 | Nephrocalcinosis-related chronic kidney disease model (mice) | [153] |
| CP-456773 (inhibitor of the NLRP3) | NLRP3 | Oxalate- or adenine-induced crystal nephropathy | [154] |
| Ginsenoside compound K | NLRP3 | High-fat diet/streptozotocin-induced diabetic nephritis (mice) | [155] |
| Unilateral ureteral obstruction model (mice) | [156] |
| FL-926-16 (carnosine derivative) | NLRP3 | db/db diabetic mice | [157] |
| Verapamil | NLRP3 | Diabetic nephropathy | [158] |
| Osthole | NLRP3 | A progressive IgAN model (mice) | [84] |
| Antroquinonol | [83] |
| Resveratrol | [159] |
| Citral | NLRP3 | LPS-induced accelerated and severe lupus nephritis model (mice) | [112] |
| Piperine | NLRP3 | Pristine-induced lupus nephritis (mice) | [160] |
| Curcumin | NLRP3 | Lupus-prone female MRL/lpr mice | [161] |
| Brilliant blue G (P2X7 antagonist) | NLRP3 | NZM2328 lupus-prone mice | [110] |
| MCC950 (inhibitor of NLRP3) | NLRP3 | NZM2328 lupus-prone mice | [111] |
|
